HC Wainwright Issues Optimistic Estimate for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities researchers at HC Wainwright raised their Q2 2027 earnings per share (EPS) estimates for BridgeBio Pharma in a research note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.43 per share for the quarter, up from their previous forecast of $0.42. HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2027 earnings at $0.68 EPS and Q4 2027 earnings at $0.88 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.52 million for the quarter, compared to analyst estimates of $178.07 million. During the same period last year, the firm posted ($0.88) EPS. The company’s quarterly revenue was up 66.8% on a year-over-year basis.

BBIO has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. William Blair began coverage on BridgeBio Pharma in a report on Tuesday, March 10th. They issued an “outperform” rating on the stock. Oppenheimer cut their price target on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Truist Financial increased their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Royal Bank Of Canada assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.19.

BridgeBio Pharma Trading Down 4.0%

BBIO stock opened at $64.68 on Tuesday. The business has a 50 day simple moving average of $71.23 and a 200-day simple moving average of $71.47. The company has a market capitalization of $12.67 billion, a P/E ratio of -17.29 and a beta of 1.02. BridgeBio Pharma has a twelve month low of $31.77 and a twelve month high of $84.94.

Insider Activity at BridgeBio Pharma

In related news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $71.58, for a total value of $143,160.00. Following the completion of the transaction, the chief accounting officer owned 134,115 shares of the company’s stock, valued at approximately $9,599,951.70. The trade was a 1.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $74.62, for a total transaction of $2,984,800.00. Following the completion of the transaction, the chief executive officer directly owned 615,686 shares of the company’s stock, valued at approximately $45,942,489.32. This represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 239,084 shares of company stock valued at $16,615,979 in the last quarter. 14.23% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC boosted its holdings in shares of BridgeBio Pharma by 271.5% in the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the period. Kemnay Advisory Services Inc. acquired a new position in BridgeBio Pharma in the fourth quarter valued at $41,000. Cary Street Partners Investment Advisory LLC boosted its holdings in BridgeBio Pharma by 861.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock valued at $43,000 after acquiring an additional 508 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in BridgeBio Pharma during the fourth quarter valued at about $44,000. 99.85% of the stock is owned by institutional investors and hedge funds.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target on BridgeBio Pharma to $110 from $100 and kept a buy rating, signaling continued optimism about the company’s growth outlook and potential upside from current levels. Article: HC Wainwright price target raise on BridgeBio Pharma
• Positive Sentiment: BridgeBio shared new data on acoramidis showing disease-modifying effects in ATTR-CM, including lower sTTR variability and fewer outpatient worsening heart-failure events, which supports the drug’s commercial and pipeline value. Article: Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
• Positive Sentiment: The company announced a $500 million stock repurchase program, which can help support the share price and may indicate management confidence in future cash flow. Article: BridgeBio Pharma Announces $500 Million Stock Repurchase Program
• Neutral Sentiment: Analysts are updating earnings estimates after BridgeBio’s first-quarter results, reflecting a reassessment of the outlook rather than a clearly bullish or bearish catalyst. Article: Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter Results
• Neutral Sentiment: Short-interest data reported no meaningful short position, so it does not appear to be a significant trading signal right now. Article: BridgeBio Pharma short interest update
• Negative Sentiment: CEO Neil Kumar sold 40,000 shares in a pre-arranged Rule 10b5-1 transaction, which can weigh on sentiment even though the sale was planned in advance. Article: SEC Form 4 insider sale by Neil Kumar

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.